132112-35-7
132112-35-7 結(jié)構(gòu)式
基本信息
(S)-1-丙基-2',6'-二甲基苯胺甲?；哙嘻}酸鹽一水合物
(s)-羅哌卡因鹽酸鹽
(-)-S)-N-(2,6-二甲基苯基)-1-正丙基哌啶-2-甲酰胺鹽酸鹽
鹽酸羅哌卡因
ROPIVACAINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE MONOHYDRATE
ROPIVCACAINE HYDROCHLORIDE
S-ROPIVACAINE HCL
(S)-ROPIVACAINE HYDROCHLORIDE
(S)-1-propyl-2',6'-dimethylanilinoformoxylpiperidine monohydrochloride monohydrate
(S)-1-propyl-2',6'-dimethylanilinoformoxylpiperidine,monohydrochloride,monohydrate
(S)-Ropivaxaine hydrochloride
(S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride
Ropivacaine hydrochloride
(2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide Hydrochloride Hydrate
LEA-103
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
制備方法
84057-95-4
132112-35-7
以(S)-N-(2,6-二甲基苯基)-1-丙基-2-哌啶羧酰胺為原料，合成(S)-N-(2,6-二甲基苯基)-1-丙基哌啶-2-甲酰胺鹽酸鹽水合物的一般步驟如下：將約3g (S)-N-(2,6-二甲基苯基)-1-丙基-2-哌啶羧酰胺溶于10mL去離子水中，向該溶液中緩慢加入50mL預(yù)熱至60°C的丙酮。在攪拌條件下，逐滴加入濃鹽酸，調(diào)節(jié)pH至2.0。隨后，將反應(yīng)混合物加熱至回流，直至形成澄清溶液。向反應(yīng)體系中追加20mL丙酮，冷卻至室溫后過(guò)濾析出的固體產(chǎn)物。用冷丙酮洗滌固體三次，于40°C真空干燥箱中干燥12小時(shí)，得到白色結(jié)晶狀(S)-N-(2,6-二甲基苯基)-1-丙基哌啶-2-甲酰胺鹽酸鹽水合物2.9g，產(chǎn)率82%。經(jīng)卡爾費(fèi)休法測(cè)定，產(chǎn)物水含量為5.6%。
參考文獻(xiàn)：
[1] Patent: US2006/276654, 2006, A1. Location in patent: Page/Page column 5
[2] Patent: US2006/276654, 2006, A1. Location in patent: Page/Page column 5
常見(jiàn)問(wèn)題列表
外科手術(shù)麻醉
-----硬膜外麻醉，包括剖宮產(chǎn)術(shù)
-----蛛網(wǎng)膜下腔麻醉
-----區(qū)域阻滯
急性疼痛控制
-----持續(xù)硬膜外輸注或間歇性單次用藥，如術(shù)后或陰道分娩鎮(zhèn)痛
-----區(qū)域阻滯
鹽酸羅哌卡因的一般副作用有低血壓、惡心、心動(dòng)過(guò)緩、焦慮、感覺(jué)減退。
IC50: sodium ion influxIC50: 402.7 μM (TREK-1 in COS-7 cell's membrane)
Ropivacaine HCl是一種局部麻醉劑。Ropivacaine HCl通過(guò)可逆抑制神經(jīng)纖維中鈉離子流引起神經(jīng)阻滯。Ropivacaine HCl的pKa是~8.2。Ropivacaine HCl在高血漿濃度下具有誘導(dǎo)心血管毒性和CNS毒性的可能性。
Epidural administration of Ropivacaine hydrochloride monohydrate effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury.
Ropivacaine hydrochloride monohydrate inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC).
Ropivacaine hydrochloride monohydrate prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats.
Ropivacaine hydrochloride monohydrate inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs.
| Animal Model: | Adult Sprague-Dawley rats (300–400g) |
| Dosage: | 1 μM |
| Administration: | Infusion (added to the perfusate reservoir) |
| Result: | Attenuated pressure-dependent increases in filtration coefficient (K f ). |
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-B0563AR | 鹽酸羅哌卡因一水合物 Ropivacaine hydrochloride monohydrate (Standard) | 132112-35-7 | 5 mg | 620元 |
| 2026/06/05 | HY-B0563AR | 鹽酸羅哌卡因一水合物 Ropivacaine hydrochloride monohydrate (Standard) | 132112-35-7 | 10 mg | 1000元 |
| 2026/06/05 | HY-B0563AR | 鹽酸羅哌卡因一水合物 Ropivacaine hydrochloride monohydrate (Standard) | 132112-35-7 | 25 mg | 1800元 |